386
Participants
Start Date
September 1, 2020
Primary Completion Date
May 31, 2022
Study Completion Date
November 30, 2022
Continuation of boosted PI
"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
B/F/TAF
Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
GHESKIO, Port-au-Prince
Collaborators (1)
Brigham and Women's Hospital
OTHER
Harvard Medical School (HMS and HSDM)
OTHER
Analysis Group, Inc.
INDUSTRY
Weill Medical College of Cornell University
OTHER
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
OTHER